nasdaqcrsp
U.S. stocks suffered their biggest one-day drop in more than two years on Tuesday.Oil & gas companies as well as auto manufacturers have managed to move higher.At the individual stock level, there have also been some interesting contrarian moversYes, the market’s strong September start was washed out by another hotter-than-expected inflation reading along with concerns that the Fed’s contractionary rate hikes could spell doom for the economy. Q2 2022 hedge fund letters, conferences and more Find A Qualified Financial AdvisorEach advisor has been vetted by SmartAsset and is held to a fiduciary ...
ValueWalk
CRISPR Therapeutics stock may offer an intriguing opportunity for investors with a long time horizon Shares of CRISPR Therapeutics (NASDAQ:CRSP) are up 4% in 2022. And long-term shareholders who have held their shares in CRSP stock for the last five years have been rewarded with a gain of over 330%. However, the stock is trading nearly 50% below its 52-week high. That means, if you were a shareholder that got in on CRSP stock near its peak, you could have a negative opinion of the stock. Q2 2022 hedge fund letters, conferences and more That's the nature of speculative stocks in areas like gene...
ValueWalk
Crispr Therapeutics AG (NASDAQ:CRSP) is a Swiss-American gene editing biotech company developing gene-based medicines. The company’s technology targets specific DNA sequences to modify, delete or correct them. The company’s platform focuses primarily on ex-Vivo programs that target sickle cell disease, β-thalassemia and B-cell malignancies. The lead program targeting sickle cell disease and β-thalassemia has entered clinical testing. Q1 2022 hedge fund letters, conferences and more CRSP shares fell from a January 2021 high of $220.20 per share in Jan. 2021 but shed 27% this year. The shares fo...
ValueWalk
As soon as you saw that there was money to be made on COVID-19 vaccinations, did you jump on board and buy COVID-19 vaccine companies? Why not expand your thinking beyond COVID-19? (However, it’s important to remember that companies like Moderna have other promising vaccines in the pipeline, such as a cytomegalovirus vaccine (mRNA-1647), a respiratory syncytial virus (RSV) vaccine for adults 60 and over (mRNA-1345) as well as its Zika vaccine (mRNA-1893). Q4 2021 hedge fund letters, conferences and more If you're reluctant to put all your eggs in the vaccine basket, why not consider life scien...
ValueWalk
閲覧を続けるには、ノアドット株式会社が「プライバシーポリシー」に定める「アクセスデータ」を取得することを含む「nor.利用規約」に同意する必要があります。
「これは何?」という方はこちら